Physician profile
Hunter Johnson
NPI 1295230183
$25,156.13
in general payments reported to CMS, 2019-2025
55 companies · $5,397 in 2025
The $5,397 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,228 · 2022: $5,448 · 2023: $6,517 · 2024: $6,567 · 2025: $5,397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $18K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $18,480.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $4,758.54 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $2,599.43 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,613.67 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $1,497.52 | 2021-2025 | |
| Amgen INC. | $1,415.05 | 2021-2025 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $1,101.43 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Otsuka America Pharmaceutical, INC. | $881.70 | 2021-2025 | Rexulti |
| Pfizer INC. | $874.19 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $818.45 | 2022-2025 | |
| Glaxosmithkline, LLC. | $715.32 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $661.80 | 2021-2025 | Jardiance, Synjardy, Spiriva Respimat |
| Axsome Therapeutics, INC. | $644.76 | 2024-2025 | Auvelity, Symbravo |
| Exact Sciences Corporation | $632.67 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $605.97 | 2022-2025 | Caplyta |
| Xeris Pharmaceuticals, INC. | $551.00 | 2022-2024 | Gvoke Hypopen, Keveyis |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hunter Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.